Skip to main content
Premium Trial:

Request an Annual Quote

Washington's PeaceHealth Joins ISB-led Personalized Medicine Initiative

NEW YORK (GenomeWeb News) – PeaceHealth, a Washington state-based non-profit health system, has partnered with the P4 Medicine institute, or P4Mi, a non-profit consortium focused on applying personalized medicine in the clinic, the partners announced today.

PeaceHealth said that its partnership with P4 Medicine, which was launched in 2010 by the Institute for Systems Biology and The Ohio State University, will ultimately provide its network of medical centers in Washington, Alaska, and Oregon with new genome-based predictive and diagnostic tools.

The non-profit said that it will work with P4Mi leaders to identify pilot projects that will be launched over the next two years in its medical practices and communities.

P4Mi is centered around the vision of advancing what Leroy Hood, ISB co-founder and president and chairman of P4Mi's board of directors, calls P4 medicine — healthcare that is predictive, preventive, personalized, and participatory.

"PeaceHealth will help us integrate emerging biologic science into community-based care models, and make innovations in wellness and health accessible to whole communities," Hood said in a statement.

"Over time, we hope to take rapidly emerging P4Mi health and wellness innovations and integrate them into everyday interactions between PeaceHealth providers and their patients to better predict, prevent, and treat disease," added Peter Adler, PeaceHealth's senior VP for strategy, innovation, and development.

The partnership agreement makes PeaceHealth a founding community health partner of P4Mi, along with OSU's Center for Personalized Health at the Wexner Medical Center.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.